(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
11 January 2007 (11.01.2007)

PCT

(10) International Publication Number
WO 2007/003525 A2

(51) International Patent Classification: Not classified

(21) International Application Number:
PCT/EP2006/063555

(22) International Filing Date: 26 June 2006 (26.06.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
05105927.7 30 June 2005 (30.06.2005) EP

(71) Applicant *(for all designated States except US)*: **JANSSEN PHARMACEUTICA N.V.** [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **ROMBOUTS, Frederik, Jan, Rita** [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). **LOVE, Christopher, John** [GB/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). **VAN EMELEN, Kristof** [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). **VAN BRANDT, Sven, Franciscus, Anna** [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). **WU, Tongfei** [CN/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE).

(74) Common Representative: **JANSSEN PHARMACEUTICA N.V.**; Turnhoutseweg 30, B-2340 Beerse (BE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— *without international search report and to be republished upon receipt of that report*

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: CYCLIC ANILINO - PYRIDINOTRIAZINES




(57) Abstract: The present invention concerns the compounds of formula (I), the *N*-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein m represents 1, n represents 1, Z represents N or C, in particular N; $-X^1-$ represents $C_{1-4}$alkyl, in particular methyl; $-X^2-$ represents $-C_{1-4}$alkyl- or $-C_{1-4}$alkyl-$NR^7-$, in particular propyl, -ethyl-$NR^7-$ or -propyl-$NR^7-$; -Y- represents-$NR^2-C_{1-6}$alkyl-CO-$NR^4-$, -Het$^1-C_{1-6}$alkyl-CO-$NR^5-$ or -Het$^2$-CO-$NR^6-$ and wherein the $-C_{1-6}$alkyl- linker of $-NR^2-C_{1-6}$alkyl-CO-$NR^4-$ or -Het$^1-C_{1-6}$alkyl-CO-$NR^5-$ is optionally substituted with one or where possible two or more substituents selected from hydroxy, halo and phenyl; $R^1$ represents hydrogen, chloro, fluoro or bromo; $R^2$ represents $-C_{1-4}$alkyl-, in particular ethyl or methyl; $R^7$ represents hydrogen; $R^8$ represents hydrogen; $R^4$, $R^5$ and $R^6$ represent hydrogen; Het$^1$ is selected from piperazinyl or piperidinyl, in particular -piperazinyl; Het$^2$ selected from pyrrolidinyl or piperidinyl, in particular pyrrolidinyl wherein said pyrrolidinyl is optionally substituted with hydroxy.

WO 2007/003525 A2